It went into a real Phase 2/3 Alzheimers trial, LIFT-AD, with 554 patients enrolled (NCT04488419), the primary efficacy analysis pre-specified in the 312 of them not taking another Alzheimers drug
Some patients benefit from using both, though we recommend discussing timing and application protocols during your consultation to ensure optimal absorption of each product
Disclaimer: BPC-157 is not an FDA-approved drug, and the Food and Drug Administration has not evaluated statements regarding its effects
A commonly used protocol involves administration five times per week for approximately eight weeks, followed by a two-week break before repeating the cycle, if appropriate
Figure 1: Changes in gross morphological scores amongst the four experimental treatment groups
Is weight loss support available